A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Daunorubicin (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Etoposide (Primary) ; Hydrocortisone (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Pegaspargase (Primary) ; Ponatinib (Primary) ; Vincristine (Primary) ; Vincristine (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda; Takeda Development Center Americas
- 08 Aug 2024 Status changed from active, no longer recruiting to completed.
- 02 Aug 2024 This trial has been Discontinued in Portugal, according to European Clinical Trials Database record.
- 27 Jul 2024 This trial has been Discontinued in Netherlands, according to European Clinical Trials Database record.